TVTX — Travere Therapeutics Share News
0.000.00%
Last trade - 00:00- $4.98bn
- $5.09bn
- $490.73m
Travere Therapeutics' Q3 revenue surges on FILSPARI growth
Brief: Travere Therapeutics Q3 EPS USD 0.28
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy
U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy
Travere jumps on US FDA's nod to skip advisory panel for kidney disease drug
U.S. STOCKS ON THE MOVE-Waldencast, Danaher, Asset Entities
Brief: Travere Therapeutics Provides Update On FDA Advisory Committee Meeting For FILSPARI In FSGS
U.S. STOCKS ON THE MOVE-Nike, US chipmakers, Greenwich LifeSciences
Travere jumps on FDA's nod to skip advisory panel for kidney disease drug
U.S. STOCKS ON THE MOVE-Victoria's Secret, Copper miners, Dell
U.S. STOCKS ON THE MOVE-Victoria's Secret, Copper miners, Dell
Travere climbs after FDA eases monitoring rules for kidney drug
Brief: Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) In IgA Nephropathy
Travere Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Travere Therapeutics' Q2 product sales up 82%
Travere Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics Announces FDA Acceptance Of SNDA For FILSPARI® (Sparsentan) In FSGS